Company intelligence / Profile preview

Disco Drug

Cologne, North Rhine-Westphalia, Germanydiscodrugstore.com ↗

Ownership: Private
Development stage: Other

Overview

DISCO Pharmaceuticals has developed a disruptive platform for mapping the surfaceome of cancer cells, enabling identification of novel druggable targets. The company has completed the first-ever comprehensive map of small cell lung cancer's surfaceome and is developing proprietary antibody-based treatments for this indication. Research into microsatellite-stable colorectal cancer and other undisclosed programs is ongoing. No clinical results have been published yet as programs remain preclinical.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibody
Industry: Biotech

Partnerships

Sofinnova PartnersPanakes PartnersM VenturesAbbVie Ventures

Beyond the preview

Go deeper on Disco Drug.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Disco Drug.

Explore the full profile